Serono bids for French biotech firm
The Swiss biotechnology firm, Serono, has offered SFr157.9 million ($105.9 million) to take over the French genomics-based biotech company, Genset.
“The offer for Genset is a continuation of our strategy of selective research and development investments,” said Ernesto Bertarelli, CEO of Serono, in a statement released on Wednesday.
“This investment will further develop our genomics drug discovery platform and feed our pipeline,” he added.
The Geneva-based firm has offered cash for all outstanding shares in the French company at a rate of €9.75 per Genset share.
At an extraordinary general meeting on Wednesday, Genset’s shareholders followed recommendations by the company’s board to accept the offer.
swissinfo with agencies
In compliance with the JTI standards
More: SWI swissinfo.ch certified by the Journalism Trust Initiative
You can find an overview of ongoing debates with our journalists here. Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.